IE
PTHS

Israel Englander’s Pelthos Therapeutics PTHS Stock Holding History

Israel Englander’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,057
Closed -$343K – 6494
2025
Q4 		$343K Buy
+11,057
New +$319K ﹤0.01% 5184
2025
Q3 		– Sell
-13,671
Closed -$172K – 6539
2025
Q2 		$172K Buy
+13,671
New +$165K ﹤0.01% 5411

Other funds holding PTHS

M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.41B AUM 25.22% 1-Year Est. Return

Israel Englander's PTHS Position: Q1 2026 in Review

Israel Englander sold out of Pelthos Therapeutics (PTHS) in Q1 2026, closing a stake of 11,057 shares — an estimated $343K sold.

Israel Englander first reported a position in PTHS in Q2 2025 and held it in 2 quarters. The position peaked at $343K in Q4 2025. 17 funds tracked by Wall St. Rank hold PTHS as of Q1 2026.

  • Israel Englander reported no remaining Pelthos Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Israel Englander sold 11,057 Pelthos Therapeutics shares in Q1 2026, an estimated $343K.
  • Israel Englander first reported a position in Pelthos Therapeutics in Q2 2025 and held it in 2 quarters.
  • Israel Englander's Pelthos Therapeutics position peaked at $343K in Q4 2025.
  • 17 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.